Navigation Links
Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008
Date:11/3/2008

ta was by intention-to-treat.

Thirty-five of 44 patients (80%) treated with a 4-week lead-in phase of nitazoxanide followed by the addition of peginterferon for 36 weeks experienced a SVR 24 weeks after the end of treatment compared to 50% in the standard of care (SOC, peginterferon alfa-2a plus ribavirin for 48 weeks) historical control group (P = 0.006), 61% in patients receiving a 12-week lead-in with nitazoxanide followed by 36 weeks of nitazoxanide plus peginterferon alfa-2a, and 79% in patients receiving a 12-week lead-in with nitazoxanide followed by 36 weeks of nitazoxanide plus SOC.

Of the 44 patients in the study, 78% (n=40) of patients with HCV genotype 4, 100% (n=3) of patients with HCV genotype 1, and 100% (n=1) of HCV genotype 2, had an SVR with undetectable virus at 24 weeks following end of treatment.

Adverse events reported for these 44 patients were similar to those reported in the STEALTH C-1 trial. Patients treated with nitazoxanide experienced no more side effects than patients who received the SOC therapy. Only one of the 44 patients discontinued therapy due to noncompliance. There were no serious adverse events or discontinuations due to adverse events.

"These data confirm findings of our STEALTH C-1 trial related to safety and efficacy of nitazoxanide in patients infected with HCV genotype 4, show that the nitazoxanide lead-in phase prior to standard of care treatment can be reduced from 12 to 4 weeks, and indicate that ribavirin may not be needed to maintain SVR," said Emmet B. Keeffe, M.D., Chief Medical Officer of Romark Laboratories.

-- "Potential Role for Nitazoxanide in Combination with STAT-C Agents

for the Inhibition of HCV Replication Without the Development of

Resistance," Korba, et al. Sunday Nov. 2, 5:30 PM PST (Oral Session

#115)

This oral presentation by Brent Korba, Ph.D. of Georgetown University Medical Center, described preclinical studies demonstr
'/>"/>

SOURCE Romark Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
3. Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... 2014 -- According to the International Atomic Energy ... comes from terrorists acquiring sufficient quantities of plutonium ... crude nuclear explosive device. The IAEA also notes ... involved gram-level quantities, which can be challenging to ... a new study appearing this week in the ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2
... 26 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) ... sites in Israel for the planned Phase II dose ... Oxycyte is the company,s perfluorocarbon (PFC) therapeutic oxygen carrier. ... planned for Switzerland."Israeli physicians are excited to be able ...
... 26 Cornerstone Therapeutics Inc. (Nasdaq: CRTX ), a specialty ... the respiratory market, today reported financial results for the year ended December ... Full-Year 2008 Net Revenues more than doubled ... , , , ...
... LASIK Surgeons directory service and website at www.TrustedLASIKSurgeons.com ... seeking to improve their vision and find a highly ... attaining 20-20 vision. What sets the Trusted LASIK ... that only those who are among the best in ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel 2Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 2Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 3Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 4Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 5Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 6Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 7Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 8Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 9Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 10Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 11Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results 12Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 2Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 3Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 4Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 5Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 6Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 7Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory 8
(Date:7/11/2014)... explored two different ways that allow unprecedented experimental ... formation of oxygen molecules in photosynthesis. The two ... Nature Communications . , "The new knowledge ... water oxidation, which are key components for building ... solar energy in fuels like hydrogen, ethanol or ...
(Date:7/11/2014)... under the normal circumstances, astrocytes participate in ... environment, and exhibit therapeutic and repairing effects ... studies have found that nerve cells differentiated ... have reduced viability, which produces influences on ... Kailuan General Hospital, Hebei United University, China ...
(Date:7/10/2014)... Santa Fe, Albuquerque, and other major cities in New ... with treated municipal wastewater rather than precious potable water ... than 40% of all golf courses receive treated effluent. ... , Additionally, golf courses and homeowners alike fertilize ... in fertilizer is nitrate. A New Mexico State University ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2'Tailored' water -- the latest in lawn care 2
... of grapes (Vitis vinifera) chiefly to make wine, is an ... from the Neolithic and Early Bronze Ages. We have a ... grape harvest leading to the concept of terroir (the range ... nature of the grapes themselves has been less well understood ...
... CRUZ, CA-- No human can survive longer than a few ... gulps of air. Our brains need a constant supply of ... seals, animals that dive and hunt under the Antarctic sea ... minutes, and remain active and mentally alert the whole time. ...
... HOUSTON (Dec. 18, 2007)Researchers at The University of ... between genes regulating glucose metabolism and spina bifida. The ... from parents and their children with that birth defect. ... dozen genes that take part in glucose metabolism to ...
Cached Biology News:Plant geneticists find veritas in vino 2Plant geneticists find veritas in vino 3Why diving marine mammals resist brain damage from low oxygen 2Why diving marine mammals resist brain damage from low oxygen 3Why diving marine mammals resist brain damage from low oxygen 4UT-Houston's Northrup and colleagues uncover genetic link to spina bifida 2
...
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
... kit contains the basic components required for ... natural and recombinant Feline IL-10 in cell ... sufficient materials to run ELISAs on approximately ... conditions are met: The assay is ...
Request Info...
Biology Products: